Lys Therapeutics
Develops monoclonal antibody LYS241 targeting neurovascular pathways for Parkinson's disease and stroke
Funding history
1 round- >€25M
Develops monoclonal antibody LYS241 targeting neurovascular pathways for Parkinson's disease and stroke